As of 2024-12-13, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -16.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 380.23 mil USD. YMAB's TTM EBITDA according to its financial statements is -22.46 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (6.37) - (7.20) | (6.45) |
| Upside | -163.7% - -171.9% | -164.5% |
| Date | EV/EBITDA |
| 2024-12-10 | -17.46 |
| 2024-12-09 | -17.42 |
| 2024-12-06 | -17.98 |
| 2024-12-05 | -17.50 |
| 2024-12-04 | -17.66 |
| 2024-12-03 | -18.04 |
| 2024-12-02 | -20.47 |
| 2024-11-29 | -20.73 |
| 2024-11-27 | -20.65 |
| 2024-11-26 | -18.44 |
| 2024-11-25 | -18.02 |
| 2024-11-22 | -17.72 |
| 2024-11-21 | -17.10 |
| 2024-11-20 | -17.98 |
| 2024-11-19 | -18.62 |
| 2024-11-18 | -18.34 |
| 2024-11-15 | -19.18 |
| 2024-11-14 | -20.08 |
| 2024-11-13 | -23.25 |
| 2024-11-12 | -23.25 |
| 2024-11-11 | -26.61 |
| 2024-11-08 | -27.83 |
| 2024-11-07 | -27.97 |
| 2024-11-06 | -28.25 |
| 2024-11-05 | -27.07 |
| 2024-11-04 | -26.61 |
| 2024-11-01 | -26.36 |
| 2024-10-31 | -25.90 |
| 2024-10-30 | -26.58 |
| 2024-10-29 | -26.36 |
| 2024-10-28 | -26.50 |
| 2024-10-25 | -25.84 |
| 2024-10-24 | -26.16 |
| 2024-10-23 | -26.61 |
| 2024-10-22 | -26.58 |
| 2024-10-21 | -26.00 |
| 2024-10-18 | -25.78 |
| 2024-10-17 | -25.28 |
| 2024-10-16 | -26.30 |
| 2024-10-15 | -25.48 |
| 2024-10-14 | -25.96 |
| 2024-10-11 | -25.88 |
| 2024-10-10 | -24.50 |
| 2024-10-09 | -25.00 |
| 2024-10-08 | -25.16 |
| 2024-10-07 | -24.96 |
| 2024-10-04 | -25.20 |
| 2024-10-03 | -23.92 |
| 2024-10-02 | -25.04 |
| 2024-10-01 | -23.31 |